• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

286.62 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Jul 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results
July 16, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
July 15, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series
June 12, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
June 03, 2026
From Alnylam Pharmaceuticals, Inc. and Inceptive
Via Business Wire
News headline image
Alnylam Issues 2025 Corporate Responsibility Report
May 19, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
May 12, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Presentations at Upcoming Investor Conferences
May 07, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
May 04, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
April 30, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation
April 20, 2026
Via Investor Brand Network
Topics Artificial Intelligence
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
April 20, 2026
Via Investor Brand Network
News headline image
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
April 20, 2026
From BioMedWire
Via GlobeNewswire
News headline image
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
April 16, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
March 30, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
March 24, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast TTR Investor Webinar
March 10, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference
February 23, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
February 19, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
February 19, 2026
From BioMedWire
Via GlobeNewswire
News headline image
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress
February 12, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results
January 29, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
January 11, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics
December 17, 2025
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
December 11, 2025
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Pharmaceuticals Announces Changes to Board of Directors
December 03, 2025
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
November 08, 2025
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
November 04, 2025
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
October 30, 2025
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
October 16, 2025
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap